#Liechtenstein #Vaduz #Implantica #Medical Device #RefluxStop

Implantica Takes Initiative to Bridge the Treatment Gap with RefluxStop

Implantica AG, a pioneering medtech company, has announced a decisive move to address the treatment gap for acid reflux patients as major competitor, Torax Medical Inc., withdraws its LINX™ Reflux Management System from the European market by March 31, 2026. With this exit, the company sees an opportunity to expand the reach of its own device, RefluxStop®, which has already demonstrated remarkable results in over 1,400 treated patients and boasts a growing network of more than 45 centers of excellence across Europe.

Dr. Peter Forsell, the founder and CEO of Implantica, expressed unwavering dedication to serving reflux patients and the medical professionals who care for them. He emphasized the potential of RefluxStop® to fill the gap left by the competition, referring to it as a game-changer for the millions who suffer from acid reflux. Unlike traditional methods that often have undesirable side effects, RefluxStop® employs an innovative approach that addresses the root cause of the issue without applying pressure to the esophagus, thus restoring its natural function.

The RefluxStop® device stands out in the field of gastroesophageal reflux disease (GERD) by reconstructing the anti-reflux barrier, which is vital for preventing acid reflux. Current surgical alternatives frequently involve encircling the esophagus, leading to complications such as swallowing difficulties or even the inability to belch. In contrast, RefluxStop® repositions and maintains the lower esophageal sphincter in its original position, enabling the body to manage reflux effectively.

As Implantica gears up for a wider roll-out of RefluxStop®, the company is also committed to providing extensive training and support for the newly established centers across Europe and the UK. This initiative looks to ensure that surgeons and gastroenterologists are well-equipped to utilize RefluxStop® and deliver positive outcomes for their patients.

The medical community has taken note of the clinical success of RefluxStop, which is CE-marked and backed by promising trial results. Implantica’s innovative device not only addresses the immediate needs of reflux patients but also adds a layer of technological advancement to gastroenterological treatments, showcasing the company’s commitment to leveraging technology in medicine.

Looking ahead, Implantica is positioning itself as a leader in the anti-reflux treatment arena, actively seeking to enhance and expand its offerings to create a future where acid reflux treatment is efficient, effective, and widely accessible. As the medical community responds to the withdrawal of the LINX™ system, all eyes are now on Implantica and the potential for RefluxStop® to transform the landscape of reflux management.

To learn more about Implantica and its products, visit www.implantica.com for additional information and updates. The company is traded on the Nasdaq First North Premier Growth Market under the ticker IMP A SDB.